1
|
Shor D, Khoo V, Jayaprakash KT. Advancing the Paradigm: Oligometastatic Disease and the Impact of Stereotactic Ablative Body Radiotherapy. Clin Oncol (R Coll Radiol) 2024:S0936-6555(24)00134-1. [PMID: 38631977 DOI: 10.1016/j.clon.2024.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Revised: 03/13/2024] [Accepted: 03/21/2024] [Indexed: 04/19/2024]
Affiliation(s)
- D Shor
- Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK.
| | - V Khoo
- The Royal Marsden Hospital NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK
| | - K T Jayaprakash
- Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, Kings Lynn, UK
| |
Collapse
|
2
|
Parikh S, Jayaprakash KT. OncoFlash-Research Updates in a Flash! (Feb 2024). Clin Oncol (R Coll Radiol) 2024; 36:67-69. [PMID: 38199674 DOI: 10.1016/j.clon.2024.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2024]
Affiliation(s)
- S Parikh
- Cancer Centre, The Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - K Thippu Jayaprakash
- Cancer Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Oncology, The Queen Elizabeth Hospital King's Lynn, King's Lynn, United Kingdom.
| |
Collapse
|
3
|
Greenwood H, Hassan J, Fife K, Ajithkumar TV, Thippu Jayaprakash K. Single-Fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic Cancers. Clin Oncol (R Coll Radiol) 2023; 35:773-786. [PMID: 37852814 DOI: 10.1016/j.clon.2023.10.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Revised: 09/14/2023] [Accepted: 10/04/2023] [Indexed: 10/20/2023]
Abstract
Stereotactic ablative body radiotherapy (SABR) consists of delivering high doses of ionising radiation, typically across three to eight fractions with high precision and conformity. SABR has become increasingly commonplace throughout the last quarter of a century and is offered for the treatment of various primary and metastatic tumour types. Delivering SABR in a single fraction has arisen as an appealing possibility for several reasons. These include fewer hospital visits, greater patient convenience, improved sustainability and lower costs. However, these factors must be balanced against considerations such as toxicity, side-effects and, most importantly, progression-free and overall survival. In this review we seek to analyse the results of studies looking at the efficacy of single-fraction SABR for lung, prostate, renal and pancreas primary tumours, as well as oligometastases. The tumour type to be most widely treated with single-fraction SABR is lung, but its remit continues to expand. We also look at the biological rationale underpinning SABR and how this can be extended to single-fraction regimens. Finally, we turn our attention towards the future directions of SABR and specifically single-fraction regimens. These include the possibility of combining SABR with immunotherapy and technological advances in the field, which could serve to expand the scope of SABR. We conclude by summarising the current clinical studies of single-fraction SABR.
Collapse
Affiliation(s)
- H Greenwood
- School of Clinical Medicine, University of Cambridge, Cambridge, UK
| | - J Hassan
- University College London Medical School, London, UK
| | - K Fife
- Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - T V Ajithkumar
- Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - K Thippu Jayaprakash
- Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Oncology, The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, UK.
| |
Collapse
|
4
|
Lorimer C, Jayaprakash KT. OncoFlash - Research Updates in a Flash! (Nov 2023). Clin Oncol (R Coll Radiol) 2023; 35:695-697. [PMID: 37798051 DOI: 10.1016/j.clon.2023.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2023]
Affiliation(s)
- C Lorimer
- University Hospitals Sussex NHS Foundation Trust, West Sussex, United Kingdom.
| | - K T Jayaprakash
- Cancer Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Oncology, The Queen Elizabeth Hospital King's Lynn, King's Lynn, United Kingdom
| |
Collapse
|
5
|
Fornacon-Wood I, Banfill K, Ahmad S, Britten A, Carson C, Dorey N, Hatton M, Hiley C, Thippu Jayaprakash K, Jegannathen A, Kidd AC, Koh P, Panakis N, Peedell C, Peters A, Pope A, Powell C, Stilwell C, Thomas B, Toy E, Wicks K, Wood V, Yahya S, Price G, Faivre-Finn C. Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK. Clin Oncol (R Coll Radiol) 2023; 35:e593-e600. [PMID: 37507280 DOI: 10.1016/j.clon.2023.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 06/13/2023] [Accepted: 07/17/2023] [Indexed: 07/30/2023]
Abstract
AIMS Previous work found that during the first wave of the COVID-19 pandemic, 34% of patients with lung cancer treated with curative-intent radiotherapy in the UK had a change to their centre's usual standard of care treatment (Banfill et al. Clin Oncol 2022;34:19-27). We present the impact of these changes on patient outcomes. MATERIALS AND METHODS The COVID-RT Lung database was a prospective multicentre UK cohort study including patients with stage I-III lung cancer referred for and/or treated with radical radiotherapy between April and October 2020. Data were collected on patient demographics, radiotherapy and systemic treatments, toxicity, relapse and death. Multivariable Cox and logistic regression were used to assess the impact of having a change to radiotherapy on survival, distant relapse and grade ≥3 acute toxicity. The impact of omitting chemotherapy on survival and relapse was assessed using multivariable Cox regression. RESULTS Patient and follow-up forms were available for 1280 patients. Seven hundred and sixty-five (59.8%) patients were aged over 70 years and 603 (47.1%) were female. The median follow-up was 213 days (119, 376). Patients with stage I-II non-small cell lung cancer (NSCLC) who had a change to their radiotherapy had no significant increase in distant relapse (P = 0.859) or death (P = 0.884); however, they did have increased odds of grade ≥3 acute toxicity (P = 0.0348). Patients with stage III NSCLC who had a change to their radiotherapy had no significant increase in distant relapse (P = 0.216) or death (P = 0.789); however, they did have increased odds of grade ≥3 acute toxicity (P < 0.001). Patients with stage III NSCLC who had their chemotherapy omitted had no significant increase in distant relapse (P = 0.0827) or death (P = 0.0661). CONCLUSION This study suggests that changes to radiotherapy and chemotherapy made in response to the COVID-19 pandemic did not significantly affect distant relapse or survival. Changes to radiotherapy, namely increased hypofractionation, led to increased odds of grade ≥3 acute toxicity. These results are important, as hypofractionated treatments can help to reduce hospital attendances in the context of potential future emergency situations.
Collapse
Affiliation(s)
| | - K Banfill
- University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| | - S Ahmad
- Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - A Britten
- Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
| | - C Carson
- The Northern Ireland Cancer Centre, Belfast, UK
| | - N Dorey
- Torbay and South Devon NHS Foundation Trust, Torquay, UK
| | - M Hatton
- Weston Park Hospital, Sheffield, UK
| | - C Hiley
- University College London Hospitals, London, UK
| | - K Thippu Jayaprakash
- Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - A Jegannathen
- University Hospitals North Midlands, Stoke on Trent, UK
| | | | - P Koh
- Royal Wolverhampton NHS Trust, Wolverhampton, UK
| | - N Panakis
- Oxford University Hospitals NHS Trust, Oxford, UK
| | - C Peedell
- The James Cook University Hospital, Middlesborough, UK
| | - A Peters
- Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - A Pope
- Clatterbridge Cancer Centre, Liverpool, UK
| | - C Powell
- Velindre Cancer Centre, Cardiff, UK
| | | | - B Thomas
- Swansea Bay University Hospital, Swansea, UK
| | - E Toy
- Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
| | - K Wicks
- University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| | - V Wood
- University Hospitals Southampton NHS Foundation Trust, Southampton, UK
| | - S Yahya
- University Hospitals Birmingham, Birmingham, UK
| | - G Price
- University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| | - C Faivre-Finn
- University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
6
|
Lorimer C, Jayaprakash KT. OncoFlash - Research Updates in a Flash! (Sept 2023). Clin Oncol (R Coll Radiol) 2023; 35:562-564. [PMID: 37574251 DOI: 10.1016/j.clon.2023.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
Affiliation(s)
- C Lorimer
- University Hospitals Sussex NHS Foundation Trust, West Sussex, United Kingdom.
| | - K T Jayaprakash
- Cancer Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Oncology, The Queen Elizabeth Hospital King's Lynn, King's Lynn, United Kingdom
| |
Collapse
|
7
|
Lorimer C, Jayaprakash KT. OncoFlash - Research Updates in a Flash! (July 2023). Clin Oncol (R Coll Radiol) 2023; 35:426-428. [PMID: 37295920 DOI: 10.1016/j.clon.2023.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Affiliation(s)
- C Lorimer
- University Hospitals Sussex NHS Foundation Trust, West Sussex, United Kingdom.
| | - K T Jayaprakash
- Cancer Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Oncology, The Queen Elizabeth Hospital King's Lynn, King's Lynn, United Kingdom
| |
Collapse
|
8
|
Simões R, Jayaprakash KT. OncoFlash - Research Updates in a Flash! (April 2023). Clin Oncol (R Coll Radiol) 2023; 35:216-218. [PMID: 36894204 DOI: 10.1016/j.clon.2023.02.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
Affiliation(s)
- R Simões
- University College London Hospitals NHS Foundation Trust, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom; Radiotherapy Trials Quality Assurance (RTTQA) Group, Northwood, United Kingdom.
| | - K T Jayaprakash
- Cancer Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Oncology, The Queen Elizabeth Hospital King's Lynn, King's Lynn, United Kingdom
| |
Collapse
|
9
|
Simões R, Jayaprakash KT. OncoFlash - Research Updates in a Flash! (February 2023). Clin Oncol (R Coll Radiol) 2023; 35:70-71. [PMID: 36639180 DOI: 10.1016/j.clon.2022.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- R Simões
- University College London Hospitals NHS Foundation Trust, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom; Radiotherapy Trials Quality Assurance (RTTQA) Group, Northwood, United Kingdom.
| | - K T Jayaprakash
- Cancer Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Oncology, The Queen Elizabeth Hospital King's Lynn, King's Lynn, United Kingdom
| |
Collapse
|
10
|
Thippu Jayaprakash K, Hanna GG, Hatton MQ. Lung Cancer in 2022 and Beyond! Clin Oncol (R Coll Radiol) 2022; 34:695-697. [PMID: 36153212 DOI: 10.1016/j.clon.2022.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Accepted: 09/02/2022] [Indexed: 01/31/2023]
Affiliation(s)
- K Thippu Jayaprakash
- Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Oncology, The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, UK.
| | - G G Hanna
- Cancer Centre, Belfast City Hospital, Belfast, UK; Queen's University Belfast, Belfast, UK
| | | |
Collapse
|
11
|
Simões R, Thippu Jayaprakash K. OncoFlash - Research Updates in a Flash! (October 2022). Clin Oncol (R Coll Radiol) 2022; 34:617-619. [PMID: 36115684 DOI: 10.1016/j.clon.2022.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- R Simões
- University College London Hospitals NHS Foundation Trust, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom; Radiotherapy Trials Quality Assurance (RTTQA) Group, Northwood, United Kingdom.
| | - K Thippu Jayaprakash
- Cancer Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Oncology, The Queen Elizabeth Hospital King's Lynn, King's Lynn, United Kingdom
| |
Collapse
|
12
|
Simões R, Jayaprakash KT. OncoFlash - Research Updates in a Flash! (June 2022). Clin Oncol (R Coll Radiol) 2022; 34:351-352. [PMID: 35512928 DOI: 10.1016/j.clon.2022.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- R Simões
- University College London Hospitals NHS Foundation Trust, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom; Radiotherapy Trials Quality Assurance (RTTQA) Group, Northwood, United Kingdom.
| | - K T Jayaprakash
- Cancer Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Oncology, The Queen Elizabeth Hospital King's Lynn, King's Lynn, United Kingdom
| |
Collapse
|
13
|
Padden-Modi M, Cheng J, Kirby R, Twyman N, Aslam S, Bulusu V, Gilligan D, Martin A, Pipalia N, Shiarli A, Yang H, Thippu Jayaprakash K. PD-0670 Minimising radical radiotherapy commencement time for lung cancer to improve clinical outcomes. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02917-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Padden-Modi M, Spivak Y, Gleeson I, Robinson A, Thippu Jayaprakash K. PO-1242 Clinical, pathological and dosimetric factors influencing outcomes in NSCLC treated with SABR. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03206-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Banfill K, Croxford W, Fornacon-Wood I, Wicks K, Ahmad S, Britten A, Carson C, Dorey N, Hatton M, Hiley C, Thippu Jayaprakash K, Jegannathen A, Koh P, Panakis N, Peedell C, Pope A, Powell C, Stilwell C, Thomas B, Toy E, Wood V, Yahya S, Zhou SY, Price G, Faivre-Finn C. Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK. Clin Oncol (R Coll Radiol) 2022; 34:19-27. [PMID: 34763964 PMCID: PMC8552552 DOI: 10.1016/j.clon.2021.10.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 09/15/2021] [Accepted: 10/18/2021] [Indexed: 12/12/2022]
Abstract
AIMS In response to the COVID-19 pandemic, guidelines on reduced fractionation for patients treated with curative-intent radiotherapy were published, aimed at reducing the number of hospital attendances and potential exposure of vulnerable patients to minimise the risk of COVID-19 infection. We describe the changes that took place in the management of patients with stage I-III lung cancer from April to October 2020. MATERIALS AND METHODS Lung Radiotherapy during the COVID-19 Pandemic (COVID-RT Lung) is a prospective multicentre UK cohort study. The inclusion criteria were: patients with stage I-III lung cancer referred for and/or treated with radical radiotherapy between 2nd April and 2nd October 2020. Patients who had had a change in their management and those who continued with standard management were included. Data on demographics, COVID-19 diagnosis, diagnostic work-up, radiotherapy and systemic treatment were collected and reported as counts and percentages. Patient characteristics associated with a change in treatment were analysed using multivariable binary logistic regression. RESULTS In total, 1553 patients were included (median age 72 years, 49% female); 93 (12%) had a change to their diagnostic investigation and 528 (34%) had a change to their treatment from their centre's standard of care as a result of the COVID-19 pandemic. Age ≥70 years, male gender and stage III disease were associated with a change in treatment on multivariable analysis. Patients who had their treatment changed had a median of 15 fractions of radiotherapy compared with a median of 20 fractions in those who did not have their treatment changed. Low rates of COVID-19 infection were seen during or after radiotherapy, with only 21 patients (1.4%) developing the disease. CONCLUSIONS The COVID-19 pandemic resulted in changes to patient treatment in line with national recommendations. The main change was an increase in hypofractionation. Further work is ongoing to analyse the impact of these changes on patient outcomes.
Collapse
Affiliation(s)
- K Banfill
- The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.
| | - W Croxford
- The Christie NHS Foundation Trust, Manchester, UK
| | | | - K Wicks
- The University of Manchester, Manchester, UK
| | - S Ahmad
- Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - A Britten
- Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
| | - C Carson
- The Northern Ireland Cancer Centre, Belfast, UK
| | - N Dorey
- Torbay and South Devon NHS Foundation Trust, Torquay, UK
| | - M Hatton
- Weston Park Hospital, Sheffield, UK
| | - C Hiley
- University College London Hospitals, London, UK
| | - K Thippu Jayaprakash
- Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - A Jegannathen
- University Hospitals North Midlands, Stoke-on-Trent, UK
| | - P Koh
- Royal Wolverhampton NHS Trust, Wolverhampton, UK
| | - N Panakis
- Oxford Universities NHS Trust, Oxford, UK
| | - C Peedell
- The James Cook University Hospital, Middlesbrough, UK
| | - A Pope
- Clatterbridge Cancer Centre, Bebington, UK
| | - C Powell
- Velindre Cancer Centre, Cardiff, UK
| | | | - B Thomas
- Swansea Bay University Hospital, Swansea, UK
| | - E Toy
- Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
| | - V Wood
- University Hospitals Southampton NHS Foundation Trust, Southampton, UK
| | - S Yahya
- University Hospitals Birmingham, Birmingham, UK
| | - S Y Zhou
- Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - G Price
- The University of Manchester, Manchester, UK
| | - C Faivre-Finn
- The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
16
|
Crockett C, Salem A, Thippu Jayaprakash K. Shooting the Star: Mitigating Respiratory Motion in Lung Cancer Radiotherapy. Clin Oncol (R Coll Radiol) 2021; 34:160-163. [PMID: 34893390 DOI: 10.1016/j.clon.2021.11.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Revised: 11/03/2021] [Accepted: 11/18/2021] [Indexed: 11/30/2022]
Affiliation(s)
- C Crockett
- Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK.
| | - A Salem
- Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK
| | - K Thippu Jayaprakash
- Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Oncology, The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, UK
| |
Collapse
|
17
|
croxford W, Banfill K, Fornacon-Wood I, Britten A, Carson C, Hatton M, Thippu Jayaprakash K, Jegannathen A, Keng Koh P, Panakis N, Peedell C, Pope A, Powell C, Stilwell C, Thomas B, Wood V, Yun Zhou S, Price G, Faivre-Finn C. PO-1198 Changes in radical radiotherapy for lung cancer patients in the UK during the COVID-19 pandemic. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07649-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Connor M, Genie M, Gonzalez M, Hosking-Jervis F, Thippu Jayaprakash K, Sarwar N, Horan G, Klimowska-Nassar N, Sukumar J, Pokrovska T, Basak D, Rai B, Robinson A, Beresford M, Mangar S, Falconer A, Dudderidge T, Khoo V, Winkler M, Watson V, Ahmed H. Metastatic prostate cancer patients’ Attitudes towards Treatment of the local Tumour and metastasis Evaluative Research (IP5-MATTER): A multicentre, discrete choice experiment trial-in-progress. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01243-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Morton-Gittens J, Pipalia N, Jayaprakash KT. 205P Impact of UK COVID-19 pandemic cancer guidelines on treatment decisions for thoracic malignancies. J Thorac Oncol 2021. [PMCID: PMC7997778 DOI: 10.1016/s1556-0864(21)02047-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
20
|
Banfill K, Price G, Wicks K, Britten A, Carson C, Hatton M, Jayaprakash KT, Jegannathen A, Lee C, Panakis N, Peedell C, Stilwell C, Pope T, Powell C, Wood V, Zhou S, Faivre-Finn C. 203MO Changes in management for patients with lung cancer treated with radical radiotherapy during the first wave of the COVID-19 pandemic in the UK (COVID-RT Lung). J Thorac Oncol 2021. [PMCID: PMC7997784 DOI: 10.1016/s1556-0864(21)02045-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/29/2022]
|
21
|
Banfill K, Price G, Peedell C, Harland K, Powell C, Panakis N, Jayaprakash KT, Mokhtar D, Hatton M, Faivre-Finn C. P09.17 Changes in the Management of Patients Having Radical Radiotherapy in the UK During the COVID-19 Pandemic (COVID-RT Lung). J Thorac Oncol 2021. [PMCID: PMC7976873 DOI: 10.1016/j.jtho.2021.01.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/29/2022]
|
22
|
Thippu Jayaprakash K, Hussein M, Nisbet A, Shaffer R, Michael A, Ajaz M. OC-0449: Pre-clinical evaluation of combining radiation with Notch signalling inhibition in melanoma. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00471-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
23
|
Thippu Jayaprakash K, Michael A. Notch Inhibition: a Promising Strategy to Improve Radiosensitivity and Curability of Radiotherapy. Clin Oncol (R Coll Radiol) 2020; 33:e44-e49. [PMID: 32680694 DOI: 10.1016/j.clon.2020.06.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 05/26/2020] [Accepted: 06/22/2020] [Indexed: 12/15/2022]
Affiliation(s)
- K Thippu Jayaprakash
- Department of Clinical and Experimental Medicine, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK; Cancer Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Oncology, The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, UK.
| | - A Michael
- Department of Clinical and Experimental Medicine, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK; Department of Oncology, St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK
| |
Collapse
|
24
|
Verghese P, Jayaprakash KT, Yip K, Screaton N, Parfrey H, Simler N, Gilligan D, Thillai M. Management of lung cancer in patients with interstitial lung disease. Lung Cancer 2020. [DOI: 10.1016/s0169-5002(20)30234-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Yang H, Jayaprakash KT, Aslam S, Jeffs Y, Jessop S, Mckay N, Cawood H, Bulusu V. Neutrophil-to-lymphocyte ratio (NLR) trends and treatment response to programmed death/ligand 1 (PD-1/PD-L1) inhibitors in non-small cell lung cancer (NSCLC). Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30141-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Thippu Jayaprakash K, Yang H, Aslam S, Jeffs Y, Jessop S, Bulusu V. Rare double mutations in epidermal growth factor receptor (EGFR) mutant adenocarcinoma of lung. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30266-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Jayaprakash KT, Rubasingham J, Ingle C, Muthukumar D. 115P Heart and pulmonary artery radiation doses in non-small cell lung cancer. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30389-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Thippu Jayaprakash K, Mostafa D, Hussein M, Nisbet A, Shaffer R, Ajaz M. EP-2312: Biological validation of a high-throughput in-vitro radiobiology platform. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32621-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Thippu Jayaprakash K, Wildschut K, Jena R. Feasibility of Hippocampal Avoidance Radiotherapy for Glioblastoma. Clin Oncol (R Coll Radiol) 2017; 29:748-752. [PMID: 28693823 DOI: 10.1016/j.clon.2017.06.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Revised: 05/24/2017] [Accepted: 05/30/2017] [Indexed: 10/19/2022]
Abstract
With improvements in survival for good performance status patients and in specific molecular subtypes of glioblastoma, some patients will survive to develop significant neurocognitive dysfunction. This retrospective planning study quantified hippocampal radiation doses in patients with glioblastoma receiving radical chemo-radiotherapy and compared this with the radiation doses that showed clinical correlation with neurocognitive dysfunction, and evaluated the potential for clinically meaningful hippocampal dose reduction using helical TomoTherapy®.
Collapse
Affiliation(s)
- K Thippu Jayaprakash
- Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
| | - K Wildschut
- Department of Radiotherapy Physics, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - R Jena
- Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Oncology, University of Cambridge, Cambridge, UK
| |
Collapse
|
30
|
Thippu Jayaprakash K, Wood K, Shaffer R. Improving Clinical Oncology Trainees' Radiotherapy Induction. Clin Oncol (R Coll Radiol) 2016; 28:e220. [DOI: 10.1016/j.clon.2016.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Revised: 07/06/2016] [Accepted: 07/10/2016] [Indexed: 11/28/2022]
|
31
|
Phillips I, Thippu Jayaprakash K, Murray P. Benefits of Stereotactic Radiotherapy Fellowships to Clinical Oncology Trainees. Clin Oncol (R Coll Radiol) 2016; 28:e221. [PMID: 27622694 DOI: 10.1016/j.clon.2016.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Revised: 08/11/2016] [Accepted: 08/25/2016] [Indexed: 11/24/2022]
Affiliation(s)
- I Phillips
- St Luke's Cancer Centre, Royal Surrey County Hospital NHS Trust, Guildford, UK; Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK
| | - K Thippu Jayaprakash
- St Luke's Cancer Centre, Royal Surrey County Hospital NHS Trust, Guildford, UK; Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK
| | - P Murray
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| |
Collapse
|
32
|
Larbi E, Thippu Jayaprakash K, Roodhouse A, Khaksar S, Wood K, Money-Kyrle J, Shaffer R. The role of oncologists in management decisions for non-metastatic muscle invasive bladder cancer (MIBC). Clin Oncol (R Coll Radiol) 2016. [DOI: 10.1016/j.clon.2016.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
Maskell D, Thippu Jayaprakash K, Sisson K, Roques T, Geropantas. Unilateral neck radiotherapy for tonsillar squamous cell carcinomas. Clin Oncol (R Coll Radiol) 2016. [DOI: 10.1016/j.clon.2016.04.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Thippu Jayaprakash K, Lightowlers S, Rimmer Y, Russell S, Benson R, Horan G. Pelvic Nodal Irradiation (PNRT) in Prostate Cancer: Cambridge Experience. Clin Oncol (R Coll Radiol) 2016. [DOI: 10.1016/j.clon.2015.12.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Thippu Jayaprakash K, Jena R, Wildschut K. EP-1647: Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32898-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
36
|
Navarro C, Thippu Jayaprakash K, Dymond S, Chris S, Turner L, Shaffer R, Adams E, Nisbet A, Jordan T. EP-1706: Evaluation of different radiosurgical planning techniques using iPlan®. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32957-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
37
|
Thippu Jayaprakash K, Geropantas K, Sisson K, Roques T. EP-1032: Unilateral neck radiotherapy in HPV-related tonsillar carcinomas. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32282-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
38
|
Thippu Jayaprakash K, Gilligan D, Harden S. 138 Stage I non small cell lung cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative radiotherapy. Lung Cancer 2016. [DOI: 10.1016/s0169-5002(16)30155-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|